Zacks Investment Research downgraded shares of RESMED INC (RMD) from OUTPERFORM to NEUTRAL on June 27, 2012, with a target price of $38.50.
ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. The company sells a comprehensive range of diagnostic and treatment devices in countries through a combination of wholly owned subsidiaries and independent distributors.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on RESMED INC (RMD),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment